---
id: acinetobacter-baumannii-CRAB_067
category: organisms
tags: [acinetobacter-baumannii, CRAB, carbapenem-resistant, colistin, ampicillin-sulbactam, cefiderocol]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Carbapenem-Resistant Acinetobacter baumannii (CRAB)

**Q:** What are the clinical characteristics, treatment challenges, and current management strategies for CRAB infections?

**A:**

**Microbiology:**
- **Gram-negative coccobacillus** (plump, "diplococcus-like" appearance)
- **Acinetobacter baumannii-calcoaceticus complex** (most clinically relevant)
- **Strict aerobe** (non-fermenter)
- **Environmental organism:** Survives on dry surfaces (weeks), hospital equipment

**Carbapenem Resistance Mechanisms:**
- **Carbapenemases:** OXA-type (OXA-23, OXA-24, OXA-58), MBLs (NDM, VIM, IMP)
- **Efflux pumps**
- **Porin loss**

---

**Epidemiology & Risk Factors:**

**Patient Risk Factors:**
- **Prolonged ICU stay**
- **Mechanical ventilation**
- **Broad-spectrum antibiotic exposure** (especially carbapenems)
- **Central venous catheters**
- **Open wounds** (burn patients, trauma)
- **Immunosuppression**
- **Recent surgery**

**Healthcare Setting:**
- **Endemic in ICUs** worldwide
- **Outbreak-associated** (contaminated equipment, healthcare workers' hands)
- Survives in environment (fomites, sinks, ventilator tubing)

**Key Point:** CRAB = **healthcare-associated pathogen** (rarely community-acquired)

---

**Clinical Syndromes:**

**1. Ventilator-Associated Pneumonia (VAP) - Most Common:**
- **Bilateral infiltrates**
- **Purulent secretions**
- High mortality (30-70%)

**2. Bloodstream Infection/Bacteremia:**
- Often catheter-associated (CLABSI)
- High mortality (40-60%)
- Risk: Septic shock, DIC

**3. Skin/Soft Tissue/Wound Infection:**
- **Burn wounds** (common)
- Surgical site infections
- Traumatic wounds (military/blast injuries)

**4. Meningitis/Ventriculitis:**
- Post-neurosurgical (EVD, VP shunt)
- High mortality (>50%)

**5. Urinary Tract Infection:**
- Usually catheter-associated (CAUTI)

---

**Diagnosis:**

**Culture:**
- Routine media (MacConkey, blood agar)
- **Lactose non-fermenting** (pale colonies on MacConkey)
- Oxidase-negative

**Carbapenem Resistance Definition:**
- **CRAB:** Resistant to imipenem, meropenem, or doripenem
- MIC ≥4 μg/mL for meropenem

**Susceptibility Testing:**
- **ESSENTIAL** - resistance varies
- Test: Ampicillin-sulbactam (high-dose), colistin, tigecycline, cefiderocol, minocycline

---

**Treatment:**

**Key Principle (IDSA 2024):**
- **No single agent is superior**
- **Combination therapy preferred** (≥2 active agents)
- **Colistin + meropenem NO longer recommended** (negative RCT data)

**1. Primary Treatment Options:**

**High-Dose Ampicillin-Sulbactam (Sulbactam Active Component):**

| **Drug** | **Dosing** | **Mechanism** |
|----------|------------|---------------|
| **Ampicillin-sulbactam (high-dose)** | 9g (amp component) IV q8h (extended infusion over 3h) **OR** 27g/day continuous infusion | **Sulbactam** has direct anti-Acinetobacter activity |

**Rationale:**
- Sulbactam (β-lactamase inhibitor) has **intrinsic activity** against Acinetobacter
- High doses achieve therapeutic levels
- **IDSA 2024:** Preferred primary combination agent

**Alternative Dosing:**
- Total daily dose: 27g ampicillin component (18g sulbactam component)
- Delivered as continuous infusion or divided q8h with extended infusion

**Colistin (Polymyxin E):**

| **Drug** | **Dosing** | **Notes** |
|----------|------------|-----------|
| **Colistin** | Loading dose: 300 mg (9 million units) IV x1<br>Maintenance: 150 mg (4.5 million units) IV q12h | Nephrotoxic, neurotoxic<br>Resistance emerging |

**Important:**
- Colistin **always in combination** (never monotherapy)
- **Colistin + meropenem NOT recommended** (negative RCT data)
- Prefer colistin + ampicillin-sulbactam

**Cefiderocol (Siderophore Cephalosporin):**

| **Drug** | **Dosing** | **Notes** |
|----------|------------|-----------|
| **Cefiderocol** | 2g IV q8h (infused over 3h) | Active against OXA-type, MBL<br>Retained activity in CRAB |

**Efficacy:**
- **2024 meta-analysis:** Cefiderocol-based regimens → 100% early clinical success (vs 63.7% colistin-based)
- Approved for CRAB treatment (FDA)
- **Concern:** Higher mortality signal in some trials (CREDIBLE-CR) - unclear causality

**Other Options:**

| **Drug** | **Dosing** | **Notes** |
|----------|------------|-----------|
| **Tigecycline** | 100 mg IV x1, then 50 mg IV q12h | Bacteriostatic<br>Avoid in bacteremia (lower serum levels)<br>Consider for pneumonia |
| **Minocycline** | 100 mg IV/PO q12h | Alternative to tigecycline<br>Better PK |
| **Eravacycline** | 1 mg/kg IV q12h | Newer tetracycline<br>Limited data for CRAB |

---

**2. IDSA 2024 Combination Strategies:**

**Preferred Combinations:**

**Option 1 (Most Common):**
- **High-dose ampicillin-sulbactam** (9g q8h extended infusion)
- PLUS **colistin** (loading 300 mg, then 150 mg q12h)

**Option 2:**
- **Cefiderocol** (2g IV q8h)
- PLUS **ampicillin-sulbactam** OR **colistin**

**Option 3 (If others unavailable):**
- **Colistin** + **tigecycline**

**NOT Recommended:**
- Colistin + meropenem (negative RCT data)

**3. Treatment by Syndrome:**

**VAP/Pneumonia:**
- High-dose ampicillin-sulbactam + colistin OR
- Cefiderocol + ampicillin-sulbactam
- Duration: 7-14 days

**Bacteremia/CLABSI:**
- Remove catheter (if possible)
- High-dose ampicillin-sulbactam + colistin OR
- Cefiderocol-based combination
- Duration: 14 days (uncomplicated), longer if metastatic foci

**Meningitis/Ventriculitis:**
- **Intraventricular colistin** (25,000-125,000 units/day) + IV therapy
- Consider cefiderocol (better CSF penetration than colistin IV alone)
- Remove infected hardware if possible
- Duration: ≥21 days

---

**Resistance & Susceptibility Patterns:**

**Typical CRAB Resistance Profile:**
- ✅ **Often susceptible:** Ampicillin-sulbactam (high-dose), colistin, tigecycline, cefiderocol, minocycline
- ❌ **Resistant:** Carbapenems (by definition), most β-lactams, fluoroquinolones, aminoglycosides

**Emerging Concerns:**
- **Colistin resistance:** 5-10% (increasing)
- **Pan-drug resistant (PDR) Acinetobacter:** Resistant to ALL agents (emerging)

---

**Infection Control:**

**Contact Precautions:**
- Gown and gloves for all patient contact
- Private room preferred

**Environmental Disinfection:**
- Daily cleaning with bleach or other sporicidal agents
- **A. baumannii survives weeks on dry surfaces** (keyboards, bedrails, BP cuffs)

**Outbreak Control:**
- Cohort patients
- Dedicated equipment
- Hand hygiene emphasis

---

**Prognosis:**

**Mortality:**
- **VAP:** 30-70%
- **Bacteremia:** 40-60%
- **Meningitis:** >50%

**Predictors of Mortality:**
- Inappropriate empiric therapy
- Delayed source control
- Severe sepsis/shock
- APACHE II score
- Pneumonia (worse than UTI)

---

**Comparison: CRAB Treatment Agents**

| **Agent** | **Pros** | **Cons** | **IDSA 2024 Role** |
|-----------|----------|----------|-------------------|
| **High-dose amp-sulbactam** | Sulbactam direct activity<br>Preferred combination agent | High doses needed<br>Ampicillin component unnecessary | ✅ **Primary agent** |
| **Colistin** | Still active (90-95%) | Nephrotoxic<br>Resistance emerging<br>Colistin+meropenem NO | ✅ **Combination partner** |
| **Cefiderocol** | Active vs OXA, MBL<br>100% early success (2024 meta-analysis) | Mortality signal (CREDIBLE-CR)<br>Expensive | ✅ **Promising alternative** |
| **Tigecycline** | Good for pneumonia | Bacteriostatic<br>Avoid bacteremia<br>Low serum levels | Alternative |
| **Minocycline** | Better PK than tigecycline | Limited data | Alternative |

---

**Mnemonic: "CRAB = Carbapenem-Resistant, Amp-sulbactam Best (high-dose), Colistin Combination"**
- **C**arbapenem-resistant
- **R**equires combination therapy
- **A**mp-sulbactam (high-dose) primary agent
- **B**est outcomes with combination (never monotherapy)

**Mnemonic: "SULBACTAM Saves (not ampicillin)"**
- **SUL**bactam has intrinsic activity against Acinetobacter
- Ampicillin component is inactive

**Clinical Pearls:**
- **CRAB = healthcare-associated** (ICU, ventilators, central lines)
- **High-dose ampicillin-sulbactam preferred** (sulbactam = active component) - 9g q8h extended infusion
- **Combination therapy essential** (IDSA 2024) - never monotherapy
- **Colistin + meropenem NO longer recommended** (negative RCT data)
- **Cefiderocol promising** (100% early success in 2024 meta-analysis, but mortality signal in some trials)
- **Pan-drug resistant (PDR) Acinetobacter emerging** - no effective agents
- **Survives weeks on dry surfaces** → environmental reservoir, outbreak risk
- **Contact precautions mandatory**
- Meningitis → consider **intraventricular colistin** + IV therapy
- Remove infected catheters/devices when possible
- **Mortality 30-70%** (VAP), 40-60% (bacteremia)

**Media:** None

**Sources:** [IDSA 2024 - AMR guidance], [BMC Infect Dis 2024 - Cefiderocol vs colistin meta-analysis], [AAC 2024 - Amp-sulbactam vs colistin for CRAB pneumonia], [PMC 2024 - CRAB treatment in real life], [MDPI 2024 - Optimizing treatment for CRAB], [Clinical trials - Cefiderocol + amp-sulbactam vs colistin], [Private Practice ID 2024 - CRAB treatment options]
